Ulimorelin

Ulimorelin

SCHEMBL11983033

C[C@@H]1C(=O)N[C@H](Cc2ccc(F)cc2)C(=O)NCCCc2ccccc2O[C@@H](C)CN[C@@H](C2CC2)C(=O)N1C

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

GHSR

The experimentally established mechanism targets of Ulimorelin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
GHSR known ✓ Q92847 20/20 1.00
CYP3A4 P08684 3/20 1.00
CYP2D6 P10635 3/20 1.00
CYP2C9 P11712 2/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ulimorelin SCHEMBL19586559 1.00 GHSR (1.00) GHSRCYP3A4CYP2D6CYP2C9
Ulimorelin SCHEMBL19958029 1.00 GHSR (1.00) GHSRCYP3A4CYP2D6CYP2C9
Ulimorelin SCHEMBL29375598 1.00 GHSR (1.00) GHSRCYP3A4CYP2D6CYP2C9
Ulimorelin SCHEMBL804500 1.00 GHSR (1.00) GHSRCYP3A4CYP2D6CYP2C9
Ulimorelin SCHEMBL12197514 1.00 GHSR (1.00) GHSRCYP3A4CYP2D6CYP2C9
Ulimorelin SCHEMBL18813859 1.00 GHSR (1.00) GHSRCYP3A4CYP2D6CYP2C9
Ulimorelin SCHEMBL19958027 1.00 GHSR (1.00) GHSRCYP3A4CYP2D6CYP2C9
Ulimorelin SCHEMBL12197513 1.00 GHSR (1.00) GHSRCYP3A4CYP2D6CYP2C9
Ulimorelin SCHEMBL29432592 0.98 GHSR (1.00) GHSRCYP3A4CYP2D6CYP2C9
SCHEMBL14092333 0.97 GHSR (1.00) GHSRCYP3A4CYP2D6CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130211045-A1 MACROCYCLIC MODULATORS OF THE GHRELIN RECEPTOR TRANZYME PHARMA INC. (CA) 2013-08-15 US disclosed
EP-1648922-B9 SPATIALLY-DEFINED MACROCYCLIC COMPOUNDS USEFUL FOR DRUG DISCOVERY TRANZYME PHARMA INC (CA) 2013-04-03 EP disclosed
EP-2319859-B1 Spatially-defined macrocyclic compounds useful for drug discovery TRANZYME PHARMA INC (CA) 2013-03-27 EP disclosed
US-8334256-B2 Pharmaceutical salts of macrocyclic modulators of the ghrelin receptor TRANZYME PHARMA INC. (CA) 2012-12-18 US disclosed
EP-1648922-B3 SPATIALLY-DEFINED MACROCYCLIC COMPOUNDS USEFUL FOR DRUG DISCOVERY TRANZYME PHARMA INC (CA) 2012-08-15 EP disclosed
EP-2319859-A2 Spatially-defined macrocyclic compounds useful for drug discovery Tranzyme Pharma Inc. (CA) 2011-05-11 EP disclosed
US-20090221689-A1 Macrocyclic Modulators of the Ghrelin Receptor TRANZYME PHARMA INC. 2009-09-03 US disclosed
US-7452862-B2 Conformationally-controlled biologically active macrocyclic small molecules as motilin antagonists or ghrelin agonists TRANZYME PHARMA, INC. (CA) 2008-11-18 US disclosed
US-7452862-B2 Conformationally-controlled biologically active macrocyclic small molecules as motilin antagonists or ghrelin agonists TRANZYME PHARMA, INC. (CA) 2008-11-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090221689-A1 Macrocyclic Modulators of the Ghrelin Receptor GHSR, GIPR, GHRHR GHSR 1/4885CYP3A4 2928/4885CYP2D6 2748/4885
US-20130211045-A1 MACROCYCLIC MODULATORS OF THE GHRELIN RECEPTOR GHSR, GIPR, GHRHR GHSR 1/4885CYP3A4 2928/4885CYP2D6 2748/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.